Singapore markets closed
Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,117.27 +644.25 (+0.98%) CMC Crypto 200
1,403.85 -14.03 (-0.99%)
AMGN Jun 2024 245.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 10:01AM EDT
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 2.1300 |
| Strike | 245.00 |
| Expiry date | 2024-06-14 |
| Day's range | 1.9400 - 1.9400 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
ZacksAmgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
ZacksViridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026
© 2024 Yahoo. All rights reserved.